Abstract
OBJECTIVE: The purpose of this study was to determine the preclinical anticonvulsant and tolerability profile of cannabidiol (CBD). BACKGROUND: Epilepsy is a chronic disorder affecting ~1[percnt] of the world’s population. ~30[percnt] of epilepsy patients experience pharmacologically intractable seizures and many suffer intolerable or undesirable side-effects. Therefore, there remains an urgent clinical need for additional effective and tolerable treatments. Here, the anticonvulsant effects and tolerability profile of plant derived CBD is described in a battery of in vitro and in vivo models. DESIGN/METHODS: The effect of CBD on status epilepticus-like epileptiform local field potentials (LFPs) induced by 4-aminopyridine application or Mg2+-free conditions in rat hippocampal brain slices was assessed by in vitro multi-electrode array recordings. Additionally, the anticonvulsant profile of CBD in vivo was investigated in five rodent models of seizure: maximal electroshock and audiogenic seizures in mice, and pentylenetetrazole, pilocarpine and penicillin-induced seizures in rats. The effects of CBD in combination with commonly used anti-epileptic drugs (AEDs) on rat seizures were also investigated. Finally, CBD’s tolerability profile in rats was investigated using the accelerating rotarod, static beam, grip strength and inclined screen assays. RESULTS: CBD significantly attenuated epileptiform LFPs in vitro. CBD exerted significant anticonvulsant effects in all in vivo models of seizure. Moreover, CBD was well-tolerated and devoid of any negative drug-drug interactions in the pentylenetetrazole and pilocarpine models of seizure when co-administrated with the AEDs: sodium valproate, phenobarbital and ethosuximide. In comparison to these AEDs, CBD did not produce any motor deficits or neurotoxicity in the tolerability assays. CONCLUSIONS: These results demonstrate promising anticonvulsant effects of CBD in a broad range of in vitro and in vivo seizure models and tolerability assays. This suggests that CBD may be a novel therapeutic candidate for a range of human epilepsies, with a potentially favorable tolerability profile, supporting further clinical investigation.
Disclosure: Dr. Jones holds stock and/or stock options in GW Pharmaceuticals. Dr. Hill has nothing to disclose. Dr. Hill has received personal compensation for activities with GW Pharmaceuticals as an employee. Dr. Peres has nothing to disclose. Dr. Hadid has nothing to disclose. Dr. Wright holds stock and/or stock options in GW Pharmaceuticals, Dr. Stephens has received research support from UCB Pharma and Pfizer Inc. Dr. Williams has received research support from GW Pharmaceuticals. Dr. Whalley has received research support from GW Pharmaceuticals.
Monday, April 20 2015, 4:35 pm-5:00 pm
- Copyright © 2015 by AAN Enterprises, Inc.
Disputes & Debates: Rapid online correspondence
REQUIREMENTS
If you are uploading a letter concerning an article:
You must have updated your disclosures within six months: http://submit.neurology.org
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.